Striatal dopamine transporter density decrease in first episode schizophrenic patients treated with risperidone;Disminución del transportador de dopamina estriatal en primeros episodios psicóticos de pacientes esquizofrénicos tratados con risperidona

Revista Espanola de Medicina Nuclear

Volumn 25, Issue 3, 2006, Pages 159-165

  Mateos, J J ^a,b   Lomena F ^a   Parellada, E ^b   Font, M ^b   Fernandez E ^b   Pavia, J ^a   Prats, A ^a   Bernardo, M ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

123I FP CIT; Dopamine transporter; Schizophrenia; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; IODINE 123; N OMEGA FLUOROPROPYL 2BETA CARBOXYMETHOXY 3BETA (4-IODOPHENYL)TROPANE; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; NERVE DEGENERATION; NEUROTRANSMISSION; PARKINSONISM; PRESYNAPTIC NERVE; PROTEIN BINDING; PROTEIN SECRETION; PSYCHOLOGIC ASSESSMENT; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 33745675384     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1157/13088411     Document Type: Article

References (42)

1. Harrison. Principios de Medicina Interna 14th ed. En: Braunwald E, editor. Madrid: McGraw-Hill Interamericana; 1989.
2. Jibson MD, Tandon R. New atypical antipsychotic medicatios. J Psychiatry Res. 1998;32:215-28.
3. Miller LG, Jankovic J. Neuroleptic approach to drug-induced movement disorders: a study of 125 patients. South Med J. 1990;83:525-32.
4. Bleuler E. Dementia praecox or the group of schizophrenias. New York: J International University Press; 1950.
5. Kraeplin E. Dementia praecox and paraphrenia. Edinburgh: University of Edinburgh; 1919.
6. Caliguri M, Lohr J, Jeste D. Parkinsonism in neuroleptic-naive schizophrenic patients. Am J Psychiatry. 1993;150:1343-8.
7. McCreadie RG, Thara R, Kamath D, Padmavati R, Latha S, Mathrubootham N, et al. Abnormal movements in never medicated Indian patients with schizophrenia. Br J Psychiatry. 1996;168:221-6.
8. McCreadie R, Padmavati R, Thara R, Srinivasan TN. Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. Br J Psychiatry. 2002;181:135-7.
9. Peralta V, Cuesta M, Campos MS. Síntomas extrapiramidales en pacientes esquizofrénicos nunca tratados con neurolépticos. Aula Médica Psiquiátrica. 2002;4:269-80.
10. Wolff A, O'Driscoll G. Motor deficits and schizophrenia: the evidence from neuroleptic-naive patients and populations at risk. J Psychiatry Neurosc. 1999;24:304-14.
11. Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry. 1990;41:1203-11.
12. Bernardo M, Parellada E, Lomeña F, Catafau AM, Font M, Gómez JC, et al. Double-blind olanzapine vs haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint. Psychiatry Res. 2001;107:87-97.
13. 123I-iodobenzamide SPECT study. J Nucl Med. 2005;46:1028-33.
14. 123I-βCIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm (Supl). 1997;50:9-24.
15. Tatsch K. Imaging of the dopaminergic system in parkinsonism with SPECT. Nucl Med Commun. 2001;22:819-27.
16. 123I] FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28:266-72.
17. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, Van Royen EA, et al. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-ebeta-(4-iodophenyl)- tropane SPECT in healthy controls and early-stage, drug-naïve Parkinson's disease. J Nucl Med. 1998;39:1143-8.
18. First MB, Spitzer RL, Williams JBW, Gibbon M: Structured Clinical Interview for DSM-IV-Patients edition (SCID-P). Washington, DC: American psychiatric Press; 1994.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, USA: Am Psychiatry Ass; 1994.
20. Guy W. Early Clinical drug Evaluation Unit (ECDEU). Rockville, USA: National Institute of Mental health. 1976;76:338.
21. Kay SR, Fisbein S, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:262-73.
22. Simpson GM, Angus JW. A rating scale for extra-pyramidal side effects. Act Psychiatry Scan (Supl). 1970;212:11-9.
23. Booij J, Tissingh G, Winogrodzca A, Van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med. 1999;26:171-82.
24. 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian Symdromes. Mov Disord. 2004;19:1175-82.
25. Verhoeff NPLG. Radiotracers imaging of dopaminergic transmission in neuropsychiatric disorders. Psychopharmacoloy. 1999;147:217-49.
26. Burn DJ, Brooks DJ. Nigral dysfunction in drug-induced Parkinsonism: an 18F-DOPA PET study. Neurology. 1993;43:552-6.
27. Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, Seeman P. Reversible drug-induced parkinsonism. Clinicopathologis study of two cases. Arch Neurol. 1982;10:644-6.
28. Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Sivälahti E, et al. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res. 2001;52:115-20.
29. Tatsch K, Scherer J, Linke R, Kerner M, Hahn K. Decrease of dopamine transporter binding in neuroleptic-free schizophrenic patients assessed with IPT-SPECT (abstr.) J Nucl Med. 1999;40:31.
30. Lieberman JA, Kinon BL, Loebel AD. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull. 1990;16:97-110.
31. Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O, et al. Striatal dopamine transporter binding in neuroleptic naïve patients with schizophrenia studied with PET. Am J Psychiatry. 2000;157:269-71.
32. Laruelle M, Abi-Dargham A, Van Dyck C, Gil R, D'Souza D, Krystal J, et al. Dopamine and serotonin transporter in patients with schizophrenia: an imaging study with 123I-CIT. Biol. Psychiatry. 2000;47:371-9.
33. 123I] FP-CIT SPECT. Schizophr Res. 2001;47:59-67.
34. l23I-β-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacol. 2004;173:27-31.
35. Rivest R, Falardeau P, Di Paolo T. Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res. 1995;692:269-72.
36. Reader TA, Ase AR, Huang N, Hebert C, Van Gelder NM. Neuroleptics and dopamine transporters. Neurochem Res. 1998;23:73-80.
37. Richelson E, Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol. 1984;104:277-86.
38. Gordon I, Weizman R, Rehavi M. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol. 1996;298:27-30.
39. Valchar M, Hanbauer I. Comparison of 3HWIN 35,428 binding, a marker for dopamine transporter, in embrionyc mesencephalic neuronal cultures with striatal membranes of adult rats. J Neurochem. 1993;60:469-76.
40. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18] fluorodopa positron emission tomography study. J Neurosci. 1998;18:5901-7.
41. 123I] FP-CIT SPECT in healthy volunteers. Eur J Nucl Med. 2000;27:867-9.
42. Seeman MV. Psychopathology in women and men: focus on female hormones. Am J Psychiatry. 1997;154:1641-7.